Drugs / BI 653048 BS
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02224105 | Mar → May 2010 | — | Boehringer Ingelheim | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BI 653048 BS | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02224105 ↗ |
| Action | Activate | “Clinical profile of the functionally selective glucocorticoid receptor agonist BI 653048 in healthy male subjects.” PMID 30908082 ↗ Apr 2019 |
| Modality | Small molecule | “a functionally selective, nonsteroidal glucocorticoid (GC)” PMID 30908082 ↗ Apr 2019 |
| Route | Oral | “following oral administration of multiple rising doses of 25 mg to 200 mg over three days” NCT02224105 ↗ |